Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
The index represents a great tool for index funds and to be used as benchmarks for active investment strategies. It is commonly used both by investment managers and institutional investors. Exchange-traded funds (ETFs) that track the NBI include the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB), ProShares UltraShort NASDAQ Biotechnology ETF (NASDAQ:BIS), Invesco NASDAQ Biotech UCITS ETF (NASDAQ:SBIO) and iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) and others.Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of market open on Monday, Dec. 20.
以裸蓋菇素為主的精神保健公司指南針路徑公司(Compass Pathways Plc)納斯達克(Standard Chartered Bank：CMPS)週五透露，已入選納斯達克生物技術指數(納斯達克股票代碼：NBI)，自12月20日(星期一)開盤起生效。
"We are proud to announce our addition to the esteemed Nasdaq Biotechnology Index," George Goldsmith, CEO and founder of Compass Pathways said. "Our inclusion in this index enables us to reach new audiences as we continue to execute on our clinical development of our investigational COMP360 psilocybin therapy in hopes of addressing the most challenging issues in mental healthcare."
我們自豪地宣佈，我們加入了受人尊敬的納斯達克生物技術指數。“喬治·戈德史密斯, Compass Pathways首席執行官兼創始人説。我們被列入這一指數使我們能夠接觸到新的受眾，因為我們繼續執行我們的COMP360裸蓋菇素治療的臨牀開發，希望解決精神保健中最具挑戰性的問題。“
The NBI is designed to track the performance of a set of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. For this year's annual reconstitution, 120 securities will be added to the Index and 16 will be removed.
NBI是旨在跟蹤一組證券的表現在納斯達克股票市場上市的有被歸類為生物技術或製藥類根據行業分類基準。對於今年的年度重組，該指數將增加120只證券，16只將被剔除。
The index represents a great tool for index funds and to be used as benchmarks for active investment strategies. It is commonly used both by investment managers and institutional investors. Exchange-traded funds (ETFs) that track the NBI include the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB), ProShares UltraShort NASDAQ Biotechnology ETF (NASDAQ:BIS), Invesco NASDAQ Biotech UCITS ETF (NASDAQ:SBIO) and iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) and others.
該指數是指數基金的一個很好的工具，可以作為積極投資策略的基準。它是投資經理和機構投資者共同使用的工具。跟蹤NBI的交易所交易基金(ETF)包括ProShares超納斯達克生物技術ETF(納斯達克：圍兜)ProShares UltraShort納斯達克生物技術ETF(納斯達克：國際清算銀行)，景順納斯達克生物科技UCITS ETF(納斯達克：SBIO)和安碩納斯達克生物技術指數基金(納斯達克：IBB)等。
More recent news from COMPASS:
來自指南針的最新消息：
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
COMPASS研究證實，裸蓋菇素治療聯合SSRI抗抑鬱藥是可能的
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways
大麻運送者和搖擺者：尾巴簽名，大大麻公司，生物收穫科學，指南針路徑
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
紐約市會議的“地平線：透視迷幻劑”著名演講者的名人錄
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
COMPASS途徑：裸蓋菇素陽性試驗，高劑量組改善超越抑鬱緩解
Price Action
價格行動
COMPASS shares traded 1.64% higher at $22.87 per share at the time of writing Friday morning.
指南針股份股價上漲1.64%，至每股22.87美元。在我寫這篇文章的時候，星期五早上。
Photo: Courtesy of Mathew Schwartz on Unsplash
圖片：由馬修·施瓦茨在Unspash上提供